Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BHSE Bull Horn		$9.97	$9.63 ▼ $11.19	$61.14M	-0.01	68,771 shs	1.18 million shs
CDTX Cidara Therapeutics	$25.50 +21.2%	$20.37	$10.14 ▼ $28.42	$319.95M	0.86	74,973 shs	278,728 shs
SLDB Solid Biosciences	$2.77 +6.9%	$3.52	$2.41 ▼ $10.37	$214.68M	2.32	1.05 million shs	4.06 million shs
TVGN Tevogen Bio	$1.13 -1.7%	$1.07	$0.26 ▼ $3.09	$207.80M	-0.82	5.04 million shs	258,764 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BHSE Bull Horn	0.00%	0.00%	0.00%	0.00%	0.00%
CDTX Cidara Therapeutics	0.00%	+37.84%	+31.17%	+6.52%	+100.63%
SLDB Solid Biosciences	0.00%	0.00%	+8.63%	-31.27%	-71.41%
TVGN Tevogen Bio	0.00%	+3.23%	+15.35%	-28.48%	+16.55%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BHSE Bull Horn	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
CDTX Cidara Therapeutics	4.4137 of 5 stars	4.6	4.0	0.0	4.6	1.7	0.8	0.0
SLDB Solid Biosciences	4.3362 of 5 stars	4.7	4.0	0.0	0.0	2.9	3.3	1.3
TVGN Tevogen Bio	3.0779 of 5 stars	3.5	2.0	0.0	0.0	1.7	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BHSE Bull Horn	0.00	N/A	N/A	N/A
CDTX Cidara Therapeutics	3.22	Buy	$41.71	63.59% Upside
SLDB Solid Biosciences	3.31	Buy	$14.89	437.51% Upside
TVGN Tevogen Bio	3.00	Buy	$7.10	528.32% Upside

Current Analyst Ratings Breakdown

Latest BHSE, CDTX, SLDB, and TVGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/16/2025	CDTX Cidara Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$35.00 ➝ $50.00
5/16/2025	SLDB Solid Biosciences	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$20.00 ➝ $17.00
5/16/2025	SLDB Solid Biosciences	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$15.00 ➝ $10.00
5/16/2025	SLDB Solid Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$18.00 ➝ $17.00
5/13/2025	SLDB Solid Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/12/2025	TVGN Tevogen Bio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/9/2025	CDTX Cidara Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$33.00 ➝ $35.00
5/9/2025	CDTX Cidara Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$46.00 ➝ $47.00
4/29/2025	CDTX Cidara Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$46.00 ➝ $46.00
4/29/2025	TVGN Tevogen Bio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
4/21/2025	TVGN Tevogen Bio	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00

(Data available from 5/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BHSE Bull Horn	N/A	N/A	N/A	7.36	($0.72) per share	N/A
CDTX Cidara Therapeutics	$302K	1,059.43	N/A	N/A	($1.82) per share	-14.01
SLDB Solid Biosciences	$8.09M	26.54	N/A	N/A	$6.27 per share	0.44
TVGN Tevogen Bio	N/A	N/A	N/A	N/A	($1.10) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BHSE Bull Horn	$15.23M	N/A	0.00	N/A	N/A	N/A	-119.46%	9.08%	N/A
CDTX Cidara Therapeutics	-$22.93M	-$29.47	N/A	N/A	N/A	-289.05%	-69.64%	-33.73%	N/A
SLDB Solid Biosciences	-$96.01M	-$2.99	N/A	N/A	N/A	N/A	-58.75%	-47.84%	5/21/2025 (Estimated)
TVGN Tevogen Bio	-$70K	N/A	0.00	∞	N/A	N/A	-396.07%	749.97%	N/A

Latest BHSE, CDTX, SLDB, and TVGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	SLDB Solid Biosciences	-$0.53	-$0.59	-$0.06	-$0.59	N/A	N/A
5/8/2025	Q1 2025	CDTX Cidara Therapeutics	-$5.45	-$1.66	+$3.79	-$1.66	N/A	N/A
3/6/2025	Q4 2024	CDTX Cidara Therapeutics	-$5.28	-$5.38	-$0.10	-$5.37	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BHSE Bull Horn	N/A	N/A	N/A	N/A	N/A
CDTX Cidara Therapeutics	N/A	N/A	N/A	N/A	N/A
SLDB Solid Biosciences	N/A	N/A	N/A	N/A	N/A
TVGN Tevogen Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BHSE Bull Horn	N/A	0.13	0.13
CDTX Cidara Therapeutics	N/A	3.54	3.54
SLDB Solid Biosciences	N/A	7.85	7.85
TVGN Tevogen Bio	N/A	0.34	0.34

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BHSE Bull Horn	74.95%
CDTX Cidara Therapeutics	35.82%
SLDB Solid Biosciences	81.46%
TVGN Tevogen Bio	N/A

Insider Ownership

Company	Insider Ownership
BHSE Bull Horn	36.60%
CDTX Cidara Therapeutics	3.89%
SLDB Solid Biosciences	1.90%
TVGN Tevogen Bio	73.24%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BHSE Bull Horn	2	5.12 million	3.24 million	Not Optionable
CDTX Cidara Therapeutics	90	12.55 million	6.51 million	No Data
SLDB Solid Biosciences	100	77.50 million	35.05 million	Optionable
TVGN Tevogen Bio	3	183.89 million	75.97 million	N/A

BHSE, CDTX, SLDB, and TVGN Headlines

Recent News About These Companies

D. Boral Capital Reiterates "Buy" Rating for Tevogen Bio (NASDAQ:TVGN)

May 14, 2025 | marketbeat.com

Tevogen Bio's (TVGN) Buy Rating Reiterated at D. Boral Capital

May 14, 2025 | americanbankingnews.com

Tevogen Bio Positions Itself as a Leader in Cost-Efficient Healthcare Amid Global Pharmaceutical Competition

May 13, 2025 | nasdaq.com

Tevogen Bio's Business Model Addresses Biopharma Industry Challenges with Cost-Efficient Innovation

May 12, 2025 | globenewswire.com

Tevogen Bio Holdings Inc. Announces Letter of Intent with CD8 Technology Services for Cell Therapy Manufacturing Facility

May 2, 2025 | nasdaq.com

Tevogen to Share Direct Registration System (DRS) Process Details Following Increased Shareholder Interest

May 2, 2025 | globenewswire.com

D. Boral Capital Reaffirms "Buy" Rating for Tevogen Bio (NASDAQ:TVGN)

May 1, 2025 | marketbeat.com

CD8 Technology Signs Letter of Intent for Tevogen Bio’s In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment

April 30, 2025 | uk.finance.yahoo.com

Why Tevogen Bio Holdings Inc.’s (TVGN) Stock Is Up 5.60%

April 30, 2025 | aaii.com

CD8 Technology Signs Letter of Intent for Tevogen Bio's In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment

April 30, 2025 | globenewswire.com

Tevogen Bio shares surge on revenue forecast

April 29, 2025 | investing.com

Tevogen Informs Public Shareholders About DRS Accounts And Differences to Brokerage Accounts

April 29, 2025 | globenewswire.com

Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ's Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald

April 29, 2025 | globenewswire.com

Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion

April 28, 2025 | globenewswire.com

Tevogen Bio revises director resignation process

April 27, 2025 | uk.investing.com

Tevogen Bio past procedure aan voor aftreden bestuurders

April 26, 2025 | nl.investing.com

Tevogen Bio Announces 2025 Annual Meeting

April 25, 2025 | globenewswire.com

Tevogen Bio (NASDAQ:TVGN) Receives "Buy" Rating from D. Boral Capital

April 23, 2025 | marketbeat.com

Tevogen Bio Inc: Tevogen Bio Commissions Databricks to Accelerate Development of PredicTcell, a Precision AI Tool for Target Prediction

April 18, 2025 | finanznachrichten.de

Tevogen, Databricks Partner to Develop Immunotherapy Prediction Model

April 17, 2025 | precisionmedicineonline.com

Tevogen Bio Finalizes Agreement for Company’s Own Cell Therapy Production Facility

April 17, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BHSE, CDTX, SLDB, and TVGN Company Descriptions

Bull Horn NASDAQ:BHSE

Bull Horn Holdings Corp. does not have significant operations. It intends to effect a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization, or other similar business combination with one or more businesses in the sports, entertainment, and brands sectors. The company was incorporated in 2018 and is based in Miami Beach, Florida.

Cidara Therapeutics NASDAQ:CDTX

$25.50 +4.46 (+21.20%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$23.63 -1.87 (-7.35%)

As of 05/16/2025 07:30 PM Eastern

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Solid Biosciences NASDAQ:SLDB

$2.77 +0.18 (+6.95%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$2.72 -0.05 (-1.66%)

As of 05/16/2025 07:57 PM Eastern

Solid Biosciences Inc., a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia. It is also developing AVB-401 for the treatment of BAG3-mediated dilated cardiomyopathy; SGT-601 to treat a rare cardiac disease characterized by mutations in the gene that codes for cardiac troponin T protein, which helps coordinate contraction of the heart muscle; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, a cardiac splicing factor that regulates alternative splicing, and codes for RNA binding motif protein 20; and AVB-202-TT to treat Friedreich's ataxia, as well as other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize new gene therapies for Duchenne; and a license agreement with the University of Washington, University of Missouri, and University of Florida. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.

Tevogen Bio NASDAQ:TVGN

$1.13 -0.02 (-1.74%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$1.11 -0.02 (-1.68%)

As of 05/16/2025 07:56 PM Eastern

Tevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time